Defensins

What it is

Defensins are a family of small (3–5 kDa) cationic antimicrobial peptides produced by neutrophils, epithelial cells, and other components of the innate immune system. The major human defensins are divided into alpha-defensins (HNP-1 through HNP-6) and beta-defensins (HBD-1 through HBD-6).

Defensins represent one of the most ancient antimicrobial defense systems in vertebrates. They have been extensively studied as research compounds and as potential therapeutics for antibiotic-resistant infections. No defensin is FDA-approved for any use in the United States.

Mechanism of action

Proposed mechanisms come from laboratory and animal research. Defensins are amphipathic peptides that, in laboratory studies, disrupt microbial cell membranes through pore formation and other mechanisms, with reported activity against gram-positive bacteria, gram-negative bacteria, fungi, and some enveloped viruses. Laboratory studies have also reported immunomodulatory effects on innate and adaptive immune cells.

Clinical evidence

Despite extensive preclinical research, defensins have faced challenges in clinical translation, including production costs, stability, and pharmacokinetics. Well-controlled human trials establishing the effectiveness and safety of any defensin as a therapy are lacking.

Why we don’t prescribe it at The Tide

Defensins are not available as FDA-approved pharmaceuticals, and the category remains primarily a research interest. This entry is provided for educational purposes only.

Side effects and contraindications

Human safety of defensins given as therapeutic agents has not been established, and long-term effects are unknown. Products sold outside regulated channels may vary in purity, dose, and sterility.